abrdn plc Buys 28,967 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

abrdn plc grew its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 18.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,180 shares of the biotechnology company’s stock after acquiring an additional 28,967 shares during the period. abrdn plc owned 0.31% of Ascendis Pharma A/S worth $25,769,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S in the 3rd quarter worth about $30,000. Blue Trust Inc. grew its stake in Ascendis Pharma A/S by 540.5% in the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 427 shares in the last quarter. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 214 shares in the last quarter. Signaturefd LLC grew its stake in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares in the last quarter. Finally, Pursue Wealth Partners LLC bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $217,000.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Stifel Nicolaus increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and an average price target of $191.57.

Ascendis Pharma A/S Trading Up 5.9 %

NASDAQ ASND opened at $129.41 on Thursday. The company has a fifty day simple moving average of $133.13 and a two-hundred day simple moving average of $132.65. The stock has a market cap of $7.85 billion, a P/E ratio of -16.02 and a beta of 0.64. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.